Hormone therapy was considered the standard of care before the publication of the Women's Health Initiative. After the study was published, the use of systemic hormone therapy dramatically decreased resulting in an increased incidence of menopausal symptoms such as hot flashes, vaginal dryness, and dyspareunia experienced by women. Use of vaginal estrogen offers women a unique alternative for relief of these symptoms. This article reviews the systemic effects of vaginally administered estrogen. Effects on serum hormone levels, vasomotor symptoms, lipid profiles, and use in women with breast cancer are reviewed. An accompanying review (J Pelvic Med Surg. 2009;15:105-114.) examines the local effects of vaginally administered estrogen.
U ntil approximately 1998, "hormone replacement therapy," or "hormone therapy" (HT) was the standard of care, buoyed by multiple observational studies that demonstrated benefit. [1] [2] [3] [4] [5] [6] The use of HT was liberally recommended to women undergoing either natural or surgical menopausal with the promise of benefits for skin, bone, serum lipids, and cardiac health as well as classic menopausal symptoms. Both the Nurses Health Study 7 and the Postmenopausal Estrogen/Progestin Interventions Trial 8 indicated that estrogen therapy had multiple benefits ranging from cardioprotective effects to improvements in bone density. 7, 8 However, these results were followed by trials that failed to find a cardioprotective benefit, 9, 10 including the Women's Health Initiative (WHI), 11 which demonstrated potential harm utilizing a global index.
In the Heart and Estrogen/Progestin Replacement Study, women with known coronary atherosclerosis were randomized to active therapy versus placebo with findings of no protective effect of HT on rates of morbidity or mortality associated with myocardial infarction. 9 Although the study showed no significant differences in the number of myocardial infarctions or coronary heart disease (CHD) deaths in the control and study groups, there were more CHD events in the hormone group and women in the hormone group experienced more venous thromboembolic events (VTE). Similarly, the Estrogen Replacement and Atherosclerosis study examined angiographic data in postmenopausal women with established atherosclerosis who were placed on combination HT, and found no benefit on progression of atherosclerosis. 10 The WHI study caused a dramatic change in the recommendations for HT. 11 Results were highly publicized, especially the early discontinuation of the study secondary to increased incidence of breast cancer and cardiovascular events. The absolute risk associated with estrogen plus progestin therapy use in 1 year per 10,000 women was 7 more CHD events, 8 more strokes, 8 more invasive breast cancers, 18 more VTEs, and 8 more pulmonary embolisms. In contrast, there were 6 fewer colorectal cancers, 5 fewer hip fractures, and 44 fewer total fractures noted. However, only in the case of VTEs were the differences statistically significant for both the nominal and adjusted confidence inter-vals. [12] [13] [14] [15] Nominal confidence intervals describe the variability in the estimates that would arise from a single trial examining data for a single outcome. In contrast, adjusted confidence intervals use group sequential methods to correct for multiple analyses over time. 11 Thus the adjusted confidence intervals are more closely related to the monitoring procedures and as such, represent a conservative assessment of the evidence. 11 One criticism of the WHI is the study population, which included a group of women who were older with a mean age of 63 years at the start of HT compared with the age of onset of menopause (51 years) and likely start of HT in clinical practice. Thus the results may not have been generalizable to the younger, postmenopausal woman. 15 Also, many women in all groups had risk factors for chronic disease including tobacco use and obesity. 15 Data from the WHI released in 2002 and subsequent papers resulted in a subsequent decrease in HT use by postmenopausal women and increase in side effects that have been a source of frustration for patients and physicians alike. [11] [12] [13] [14] 16, 17 While many women abandoned hormone replacement therapy following the negative press from the WHI, they were not left with an effective alternative to alleviate their menopausal symptoms. While the data of the WHI continues to be examined in additional studies of population subsets of subjects that took oral estrogen and progesterone, vaginally administered estrogen offers a unique alternative to oral therapy for some menopausal symptoms. The currently available options for vaginally administered hormones include estradiol or conjugated equine estrogen (CEE) vaginal cream, vaginal rings (VRs) with estradiol or a combination of estradiol and progesterone, and estradiol vaginal tablets. The purpose of this review is to describe the systemic effects of vaginally administered estrogen.
MENOPAUSAL SYMPTOMS
The effect of symptoms of menopause ranges from minimal to debilitating. Vasomotor symptoms such as hot flashes and night sweats significantly affect quality of life. Although vasomotor symptoms often improve over time, urogenital symptoms do not show improvement and generally worsen with aging. 15 Atrophic vaginitis is a common condition for postmenopausal women, which results in the sensation of vaginal dryness and dyspareunia, in up to 45% of patients. 18 In addition, women experience increased rates of urinary tract infections as well as incontinence after menopause. 19 With decreasing estrogen levels, women also experience decreased bone mass associated with an increased rate of fractures and cardiovascular disease rates that approach male levels at the same age. With the conflicting results from the use of oral HT, the use of vaginally available hormones may play an important role in the spectrum of therapeutic options for menopausal women. 19 
THE VAGINA AS DRUG DELIVERY SYSTEM
A detailed description of the vagina as a drug delivery system germane to this review is presented in the companion review "Local Effects of Vaginally Administered Estrogen Therapy: A Review." 19a
EFFECTS OF VAGINAL ESTROGEN ON SERUM HORMONES
One way to predict the systemic effects of vaginally administered estrogen is to examine changes in serum hormone levels. In postmenopausal women not on HT, reported estradiol levels average 14.1 Ϯ 0.9 pg/mL and estrone levels average 27.5 Ϯ 1.2 pg/mL. 20 The mean level of luteinizing hormone (LH) and follicle stimulating hormone (FSH) is 475 ng/mL and 2007 ng/mL, respectively. 21 Rigg et al measured the levels of estradiol, estrone, LH, and FSH after application of 2 g of vaginal cream containing either 0.2 mg estradiol (E 2 ), 2.0 mg estradiol (E 2 ), or 1.25 mg CEE in 6 postmenopausal women. 20 Each participant rotated treatment with each type of cream. With the low dose estradiol (0.2 mg), an increase in serum estradiol was seen in 30 minutes with a peak of 80 Ϯ 19 pg/mL reached at 4 hours. In comparison, the high dose estradiol cream (2.0 mg) led to an increase in serum estradiol that occurred in 15 minutes with its peak occurring in 4 hours at 527 Ϯ 45 pg/mL. CEE cream showed a much slower rise of estradiol level, with a significant increase occurring after 3 hours and a peak reached at 6 hours of 33 Ϯ 6.6 pg/mL. The low dose estradiol cream did not increase serum estrone levels until after 3 hours and was 1.6 times the basal level of estrone at 8 hours (43 Ϯ 5.5pg/mL). The high dose estradiol intravaginal cream resulted in an increase of serum estrone after 1 hour, and the estrone levels continued to increase over the 24 hours of observation. In contrast, the CEE intravaginal cream resulted in an increase of estrone after 2 hours and had a peak at 8 hours of 73 Ϯ 9.2 pg/mL. CEE had a greater effect on serum estrone compared with estradiol levels. Both low-and high-dose intravaginal estradiol cream caused a greater decrease in FSH and LH than intravaginal CEE cream. 20 In a study of 20 postmenopausal women who were at least 1 year postmenopausal, several doses of CEE (0.3, 0.625, 1.25, and 2.5 mg) were tested intravaginally for effects on levels of estrone, estradiol, LH, and FSH. 21 Serum estrone levels were elevated greater than premenopausal late follicular phase with the CEE 2.5 mg dose (approximately 150 pg/mL compared with late follicular phase premenopausal control levels of approximately 125 pg/mL) while serum estradiol reached a level similar to the premenopausal control range (early follicular phase levels of approximately 65 pg/mL). Both FSH and LH levels decreased slightly with increasing dosage of CEE; however, both remained higher than premenopausal levels.
Dorr in 2007 reported that vaginal administration of 0.3 mg CEE cream resulted in lower systemic levels of both estradiol and estrone than oral administration of CEE 0.3 mg. 22 Serum estradiol levels reached a maximum of 12.8 pg/mL with the 0.3 mg vaginal CEE cream compared with 19.4 pg/mL approximately 8 hours after oral administration. Estrone levels reached 42 pg/mL with the intravaginal cream and 70.2 pg/mL with the oral tablets. 22 An FDA-approved tablet form of estradiol (Vagifem) contains 25.8 g estradiol. Recommended dosing is daily intravaginal use for 2 weeks to be followed by twice weekly administration. It is well absorbed through the vaginal epithelium and circumvents the "first pass" hepatic metabolism noted with oral administration. Serum levels of estradiol and estrone are within the menopausal range after 12 weeks of use (Estradiol C max (pg/mL) 49 Ϯ 27 on day 84, estrone C max (pg/mL) 35 Ϯ 12 on day 84 (source Vagifem package insert). Vagifem is indicated for vaginal symptoms associated with menopause. According to package insert information, Vagifem was noted to be better in improving vaginal symptoms as measured by a severity scale including dryness, soreness, and irritation compared with placebo. 23 Intravaginal estradiol is also used in women undergoing embryo transfer. Tourgeman et al studied oral versus vaginal estrogen administered to women preparing for embryo transfer. 24 The women were given leuprolide, inducing a temporary menopausal state, and then administered either oral micronized estradiol (2 mg b.i.d. orally or vaginally) during days 15 to 21 of their cycle. Two hours after the final dose of oral estradiol, mean serum levels were 279 pg/mL compared with mean serum levels following vaginal estradiol (2344 pg/mL). After homogenization of endometrial tissue biopsy specimens, estradiol levels in endometrial tissue were also determined. Orally administered estradiol resulted in 13 pg/mg endometrial protein while vaginal application resulted in 918 pg/mg protein. Although vaginally administered estradiol resulted in 10 times higher levels of serum estradiol, the endometrium showed levels 70 times higher, suggesting that the endometrium has preferential absorption. 24 In a study by Martin et al 25 postmenopausal women were given 0.5 mg vaginal micronized estradiol as a 1 time dose. Another group was given 0.5 mg vaginally with alternate day dosing for 14 days. The levels of estradiol, estrone, and gonadotropins were analyzed at 2-, 4-, 6-, 8-, 10-, and 24-hour postapplication. With the 1 time dose, estradiol reached a mean peak level of 1105 Ϯ 160 pg/mL at 4 hours. At 10 hours, the estradiol level was 24 times baseline levels. In contrast, estrone reached 11 times baseline after 8 hours (exact values not given, approximately 400 pg/mL vs. 0). There was a significant decrease in both FSH and LH during the first 10 hours (FSH approximately 90 -70 mIU/mL, and LH 40 -25 mIU/mL). 25 These data were compared with an earlier study in which 2 mg oral estradiol was used. Use of vaginal estradiol 0.5 mg resulted in a peak serum estradiol 10 times higher than 2 mg oral estradiol (0.5 mg of vaginal estradiol resulted in mean peak levels of 1105 pg/mL at 4 hours as noted earlier versus 2.0 mg oral estradiol resulted in peak level of 110 pg/mL at 2 hours). Estrone levels were 25% higher with the vaginal application. Oral delivery of estradiol yielded serum levels of estrone, which significantly exceeded levels of serum estradiol secondary to hepatic "first pass" metabolism. However, vaginal administration of estradiol results in higher serum levels of estradiol compared with estrone because the vaginally administered estradiol is not subject to "first pass" metabolism. 25, 26 
VAGINAL ESTROGEN AND VASOMOTOR SYMPTOMS
Studies of vaginally administered estrogen, both by rings and suppositories, have demonstrated relief of menopausal symptoms. Femring is a silicone elastomer VR with a central core of estradiol acetate. There are 2 doses available: 12.4 or 24.8 mg of estradiol acetate delivering 50 g and 100 g of 17␤ estradiol. This form of intravaginally administered estradiol was studied in postmenopausal women by Speroff for the United States Vaginal Ring (VR) Investigational Group. 27 Both formulations were significantly better than placebo in decreasing both the number, frequency, and severity of moderate-to-severe vasomotor symptoms. 27 By week 12, the number of moderate and severe vasomotor symptoms in the placebo group was 42.2 versus 15.5 in the 50 g E 2 ring and 8.3 in the 100 g ring (P Ͻ 0.05).
Foidart et al studied 109 women treated with vaginal suppositories containing 3.5 g estriol twice weekly for 3 weeks followed by 1 suppository weekly for 6 months or placebo and demonstrated significant reduction in vasomotor symptoms as assessed by the Kupperman index including hot flushes and other symptoms. 28 Likewise, Vartiainen et al studied the effects of a VR containing 53 mg of 17␤ estradiol versus placebo on vasomotor symptoms in 26 women. Women treated with the estradiol-containing ring demonstrated a significant reduction in symptoms. 29, 30 Serum estradiol levels similar to the follicular phase of premenopausal menstrual cycles were measured after 1 month of use and serum estradiol levels remained above post menopausal values. FSH was suppressed, however, LH was not. Postmenopausal complaints were reduced during use of the ring.
VAGINAL ESTROGEN: LIPID PROFILES AND BONE DENSITY
Vaginal estrogen therapy may have a positive effect on serum lipid profiles. In a recent study, women aged more than 60 years were randomized to receive Estring (7.5 g) or placebo. Compared with controls, the treatment group was noted to have nonsignificant increases in serum estrone (16%) and estradiol (13%); however, Estring resulted in a decrease in LDL by 7.6%, an increase in HDL by 25%, and a decrease in total cholesterol by 4%. These results are similar to the effects of commonly used patches and oral CEE. 31 In another study, Naessen et al studied changes in serum lipids in 70 healthy women greater than 60 years treated with a VR delivering E 2 7.5 g per 24 hours (Estring) or placebo for 12 months. Estring treatment was associated with nonsignifi-cant increases in estrone (ϩ16%), and estradiol (ϩ13%) within the normal postmenopausal range. The serum LDL cholesterol decreased by 7.6% (P ϭ 0.014) and LDL to HDL ratio by 7.3% (P ϭ 0.030). Total cholesterol levels were significantly reduced (4%), and triglycerides were not increased. No significant changes were noted in the control group. The authors concluded that ultra-low doses of E 2 may improve lipid levels in older women with a pattern and magnitude similar to that previously reported for conventional estrogen doses or first generation lipid lowering agents. 31 Estrogen plays a very important role in bone health. In a study of postmenopausal women, a serum estradiol level less than 5 pg/mL resulted in an increased relative risk (RR) of 2.5 for hip and vertebral fractures compared with postmenopausal women with estradiol levels greater than 5 pg/mL. 32 In addition, if sex hormone binding globulin levels were higher than 1 g/dL, the RR was 2.0 for hip fracture and 2.3 for vertebral fracture compared with those with a lower sex hormone binding globulin level. 32 Although oral estrogen replacement therapy is known to improve bone health as shown in the postmenopausal estrogen/progestin interventions and WHI trials, it is unclear whether long-term use of vaginal estrogen is protective of bone mineral density. In a randomized trial of Estring 7.5 g/d versus placebo in women over 60 years, after 6 months, individuals who received Estring had an increase in their forearm density of 2.1% compared with individuals on placebo who had a decrease of 2.7%. 33 There was a decrease in osteocalcin and alkaline phosphatase in those taking Estring, suggesting reduced turnover, while individuals on placebo had no change in these markers. Thus, even low dose vaginal estrogen may result in favorable effects on bone. 33 
VAGINAL ESTROGEN AND BREAST CANCER
Another controversy in HT is its use for menopausal symptoms after a diagnosis of breast cancer. Currently, women with breast cancer often suffer from menopausal symp-toms because they may be diagnosed while premenopausal and oophorectomy may be performed as part of the therapeutic regimen. In addition, adjuvant treatments for breast cancer, including chemotherapy regimens, can result in premature ovarian failure, and aromatase inhibitors, which have antiestrogen mechanisms, can cause marked menopausal symptoms. Serum estradiol levels average 500 pmol/mL (136.2 pg/mL) in premenopausal women and decrease to approximately 25 pmol/L (6.81pg/mL) in postmenopausal women. 34 Standard oral estrogen therapy results in an average estradiol level of 170 pmol/L. 34 The WHI showed an increase in the RR of developing breast cancer with combined HT, using oral CEE 0.625 mg and medroxyprogesterone acetate 2.5 mg above controls. 11 Vaginal estrogen use may be ideal for the treatment of menopausal symptoms in women following a diagnosis of breast cancer. As noted earlier, most forms of vaginal estrogen, with the exception of high dose vaginal cream and Femring lead to serum estradiol levels that are within the menopausal range. The goal of vaginal estrogen in these cases would to be to relieve local symptoms without an increase in serum estrogen levels. For urogenital symptoms, the VR that provides 5 to 10 g/d locally and results in no increased serum estradiol, even if an ultrasensitive bioassay is used, meets these requirements. If vaginal estradiol less than 25 g twice weekly or vaginal estriol less than 0.5 mg twice weekly is administered, there is no associated increase in serum estrogen. 34 Expert opinion suggests that oral and transdermal HT are currently contraindicated for at least some women with a diagnosis of breast cancer. 34 However, vaginal estrogen may provide relief of vaginal symptoms without an increase in serum levels (Table 1) . 34 An exception to this situation, however, may exist in women taking aromatase inhibitors. A recent study reported that in women using aromatase inhibitors, baseline serum estradiol was less than 5 pmol/L (1.36 pg/mL). After 2 weeks use of Vagifem vaginal 
CONCLUSION
Intravaginal estrogen is an important option which physicians may use for the symptomatic treatment of menopausal symptoms. Intravaginally administered estrogen can have effects beyond treatment of atrophic vaginitis, including improvement of vasomotor symptoms, and possibly lipid profiles and bone density. For women with breast cancer, low dose intravaginal estrogen may be an option for treatment of urogenital symptoms. It is unclear what endometrial cancer risk elevation is associated with intravaginal estrogen, and thus some authors recommend periodic progesterone, while others cite data showing very low rates of hyperplasia to support no need for periodic progesterone or biopsy (see other review).
The role of vaginal estrogen will continue to increase in the treatment of menopausal symptoms secondary to a lower side effect profile compared with oral administration as well as patients' tolerance and high level of satisfaction with its use. 36, 37 One potential limiting factor for the use of vaginal estrogen is patients' misinformation about vaginal anatomy. If patients can be reassured about ease of administration and effectiveness for symptoms, they will be more likely to continue use and obtain symptom relief resulting in improved quality of life.
